论文部分内容阅读
为了解卡介菌多糖核酸注射液(BCG_PSN)对哮喘的治疗效果 ,将国内93名3岁～12岁轻度～中度哮喘患儿分为3组 ,第一组BCG_PSN注射组26例 ,第二组BCG_PSN +吸入激素组34例 ,第三组单纯吸入激素组33例 ;观察用药3个月后的血清总IgE、皮肤PPD试验、临床疗效及肺功能变化。结果 :给予BCG_PSN治疗的两组 ,治疗后总IgE比治疗前有显著降低 ;29.2 %的原PPD阴性的哮喘儿童PPD转阳。评定3组的疗效 ,BCG_PSN注射组治疗总有效率57.6 % ,吸入激素组75.7 % ,BCG_PSN注射 +吸入激素组则可达到88.2 % ;且3组肺功能均能得到改善。提示BCG_PSN对哮喘患儿的免疫失衡有调节作用 ,可取得一定的哮喘治疗效果
To understand the therapeutic effect of BCG-PSN on asthma, 93 children with mild to moderate asthma aged from 3 to 12 years old were divided into three groups. The first group received 26 cases of BCG-PSN injection group 34 cases of BCG-PSN + inhalation hormone group and 33 cases of inhalation hormone group of the third group. The total serum IgE, skin PPD test, clinical efficacy and pulmonary function changes were observed after 3 months. Results: The total IgE of the two groups treated with BCG_PSN was significantly lower than that before treatment, while 29.2% of the original PPD-negative asthma children with PPD turned positive. The curative effect of three groups was evaluated. The total effective rate of BCG_PSN injection group was 57.6%, inhalation hormone group was 75.7%, BCG_PSN injection + inhalation hormone group was 88.2%, and the lung function of three groups could be improved. Tip BCG_PSN immune imbalance in children with asthma have a regulatory role, can achieve a certain degree of asthma treatment